Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224003 · ClinicalTrials.gov registry record · Phase 4
Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients
A Phase 4 study, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT00224003 is a Phase 4 study that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 23 participants.
The verdict
NCT00224003, a Phase 4 study, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
A phase 4 clinical investigation in iron-replete pediatric hemodialysis patients, whose legal guardian had provided signed informed consent, and who had satisfied the inclusion and exclusion criteria of the study.
Interventions
- DRUG Sodium Ferric Gluconate Complex in Sucrose.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2003-04 |
| Est. Completion | 2005-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00224003
The ClinicalTrials.gov registry entry for NCT00224003 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sodium Ferric Gluconate Complex in Sucrose. is the first listed.
NCT00224003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00224003 about?
NCT00224003 is a clinical study titled "Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients". A phase 4 clinical investigation in iron-replete pediatric hemodialysis patients, whose legal guardian had provided signed informed consent, and who had satisfied the inclusion and exclusion criteria of the study.
What is the current status of trial NCT00224003?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2003-04. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00224003?
The interventions under investigation include: Sodium Ferric Gluconate Complex in Sucrose. (DRUG).
Who is sponsoring clinical trial NCT00224003?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.